Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways

References

• SuN, YangJ, XieY, et al. Bone function, dysfunction and its role in diseases including critical illness. Int J Biol Sci. 2019;15(4):776–787. doi:10.7150/ijbs.2706330906209
   PubMed Web of Science ®Google Scholar
• CaoX. Targeting osteoclast-osteoblast communication. Nat Med. 2011;17(11):1344–1346. doi:10.1038/nm.249922064408
   PubMed Web of Science ®Google Scholar
• CompstonJE, McClungMR, LeslieWD. Osteoporosis. Lancet (London, England). 2019;393(10169):364–376. doi:10.1016/S0140-6736(18)32112-3
   PubMed Web of Science ®Google Scholar
• MilatF, EbelingPR. Osteoporosis treatment: a missed opportunity. Med J Aust. 2016;205(4):185–190. doi:10.5694/mja16.0056827510350
   PubMed Web of Science ®Google Scholar
• ReidIR. Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med. 2015;277(6):690–706. doi:10.1111/joim.1233925495429
   PubMed Web of Science ®Google Scholar
• FengX. RANKing intracellular signaling in osteoclasts. IUBMB Life. 2005;57(6):389–395. doi:10.1080/1521654050013766916012047
   PubMed Web of Science ®Google Scholar
• ChenR, LiuG, SunX, et al. Chitosan derived nitrogen-doped carbon dots suppress osteoclastic osteolysis via downregulating ROS. Nanoscale. 2020;12(30):16229–16244. doi:10.1039/D0NR02848G32706362
   PubMed Web of Science ®Google Scholar
• NakashimaT, TakayanagiH. New regulation mechanisms of osteoclast differentiation. Ann N Y Acad Sci. 2011;1240:E13–18. doi:10.1111/j.1749-6632.2011.06373.x22360322
   PubMed Web of Science ®Google Scholar
• WagnerEF. Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann Rheum Dis. 2010;69(Suppl 1):i86–88. doi:10.1136/ard.2009.11939619995753
   PubMed Web of Science ®Google Scholar
• TakayanagiH, KimS, KogaT, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889–901. doi:10.1016/S1534-5807(02)00369-612479813
   PubMed Web of Science ®Google Scholar
• FretzJA, ShevdeNK, SinghS, DarnayBG, PikeJW. Receptor activator of nuclear factor-kappaB ligand-induced nuclear factor of activated T cells (C1) autoregulates its own expression in osteoclasts and mediates the up-regulation of tartrate-resistant acid phosphatase. Mol Endocrinol. 2008;22(3):737–750. doi:10.1210/me.2007-033318063694
   PubMedGoogle Scholar
• SunY, GaoLL, TangMY, FengBM, PeiYH, YasukawaK. Triterpenoids from Euphorbia maculata and Their Anti-Inflammatory Effects. Molecules (Basel, Switzerland). 2018;23:9. doi:10.3390/molecules23092112
   Web of Science ®Google Scholar
• Buffa FilhoW, CorsinoJ, da BolzaniSV, FurlanM, PereiraAM, FrancaSC. Quantitative determination for cytotoxic Friedo-nor-oleanane derivatives from five morphological types of Maytenus ilicifolia (Celastraceae) by reverse-phase high-performance liquid chromatography. Phytochem Anal. 2002;13(2):75–78. doi:10.1002/pca.62612018026
   PubMed Web of Science ®Google Scholar
• LiJJ, YanYY, SunHM, et al. Anti-cancer effects of pristimerin and the mechanisms: a critical review. Front Pharmacol. 2019;10:746. doi:10.3389/fphar.2019.0074631354475
   PubMed Web of Science ®Google Scholar
• TongL, NanjundaiahSM, VenkateshaSH, AstryB, YuH, MoudgilKD. Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage. Clin Immunol. 2014;155(2):220–230. doi:10.1016/j.clim.2014.09.01425308129
   PubMed Web of Science ®Google Scholar
• XiaoY, LiK, WangZ, et al. Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling. J Cell Physiol. 2019;234(8):13959–13968. doi:10.1002/jcp.2807930633330
   PubMed Web of Science ®Google Scholar
• JurdicP, SaltelF, ChabadelA, DestaingO. Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol. 2006;85(3–4):195–202. doi:10.1016/j.ejcb.2005.09.00816546562
   PubMed Web of Science ®Google Scholar
• JacobsMD, HarrisonSC. Structure of an IkappaBalpha/NF-kappaB complex. Cell. 1998;95(6):749–758. doi:10.1016/S0092-8674(00)81698-09865693
   PubMed Web of Science ®Google Scholar
• AraiA, MizoguchiT, HaradaS, et al. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. J Cell Sci. 2012;125(Pt 12):2910–2917. doi:10.1242/jcs.09998622454522
   PubMed Web of Science ®Google Scholar
• BalkanW, MartinezAF, FernandezI, RodriguezMA, PangM, TroenBR. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Gene. 2009;446(2):90–98. doi:10.1016/j.gene.2009.06.01319563866
   PubMed Web of Science ®Google Scholar
• D’AmelioP, GrimaldiA, Di BellaS, et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone. 2008;43(1):92–100. doi:10.1016/j.bone.2008.02.017.18407820
   PubMed Web of Science ®Google Scholar
• BrommageR. New targets and emergent therapies for osteoporosis. Handb Exp Pharmacol. 2020;262:451–473. doi:10.1007/164_2019_329.
   Google Scholar
• ZhangJ, SaagKG, CurtisJR. Long-term safety concerns of antiresorptive therapy. Rheum Dis Clin North Am. 2011;37(3):387–400, vi. doi:10.1016/j.rdc.2011.08.00122023898
   PubMed Web of Science ®Google Scholar
• NiampokaC, SuttisriR, BavovadaR, TakayamaH, AimiN. Potentially cytotoxic triterpenoids from the root bark of Siphonodon celastrineus Griff. Arch Pharm Res. 2005;28(5):546–549. doi:10.1007/BF0297775615974440
   PubMed Web of Science ®Google Scholar
• CostaPM, FerreiraPM, Bolzani VdaS, et al. Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol in Vitro. 2008;22(4):854–863. doi:10.1016/j.tiv.2008.01.00318296021
   PubMed Web of Science ®Google Scholar
• DirschVM, KiemerAK, WagnerH, VollmarAM. The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol. 1997;336(2–3):211–217. doi:10.1016/S0014-2999(97)01245-49384235
   PubMed Web of Science ®Google Scholar
• HuangS, HeP, PengX, LiJ, XuD, TangY. Pristimerin inhibits prostate cancer bone metastasis by targeting PC-3 stem cell characteristics and VEGF-induced vasculogenesis of BM-EPCs. Cell Physiol Biochem. 2015;37(1):253–268. doi:10.1159/00043035026302893
   PubMedGoogle Scholar
• YanYY, BaiJP, XieY, YuJZ, MaCG. The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction. Oncol Lett. 2013;5(1):242–248. doi:10.3892/ol.2012.98223255929
   PubMed Web of Science ®Google Scholar
• KobayashiN, KadonoY, NaitoA, et al. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 2001;20(6):1271–1280. doi:10.1093/emboj/20.6.127111250893
   PubMed Web of Science ®Google Scholar
• RuoccoMG, MaedaS, ParkJM, et al. I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med. 2005;201(10):1677–1687. doi:10.1084/jem.2004208115897281
   PubMed Web of Science ®Google Scholar
• IotsovaV, CaamanoJ, LoyJ, YangY, LewinA, BravoR. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med. 1997;3(11):1285–1289. doi:10.1038/nm1197-12859359707
   PubMed Web of Science ®Google Scholar
• TiedemannRE, SchmidtJ, KeatsJJ, et al. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood. 2009;113(17):4027–4037. doi:10.1182/blood-2008-09-17979619096011
   PubMed Web of Science ®Google Scholar
• WangY, ZhouY, ZhouH, et al. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. PLoS One. 2012;7(8):e43826. doi:10.1371/journal.pone.004382622952775
   PubMed Web of Science ®Google Scholar
• GaoX, LiuY, DeebD, ArbabAS, GautamSC. Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-kappaB/mTOR signaling. J Exp Ther Oncol. 2014;10(4):275–283.25509983
   PubMedGoogle Scholar
• TuY, TanF, ZhouJ, PanJ. Pristimerin targeting NF-kappaB pathway inhibits proliferation, migration, and invasion in esophageal squamous cell carcinoma cells. Cell Biochem Funct. 2018;36(4):228–240. doi:10.1002/cbf.333529781107
   PubMed Web of Science ®Google Scholar
• MizukamiJ, TakaesuG, AkatsukaH, et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol. 2002;22(4):992–1000. doi:10.1128/MCB.22.4.992-1000.200211809792
   PubMed Web of Science ®Google Scholar
• HeY, StaserK, RhodesSD, et al. Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One. 2011;6(9):e24780. doi:10.1371/journal.pone.002478021961044
   PubMed Web of Science ®Google Scholar
• DavidJP, SabapathyK, HoffmannO, IdarragaMH, WagnerEF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci. 2002;115(Pt 22):4317–4325. doi:10.1242/jcs.0008212376563
   PubMed Web of Science ®Google Scholar
• NakamuraH, HirataA, TsujiT, YamamotoT. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Mineral Res. 2003;18(7):1198–1205. doi:10.1359/jbmr.2003.18.7.1198
   PubMed Web of Science ®Google Scholar
• LeeK, ChungYH, AhnH, KimH, RhoJ, JeongD. Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation. Int J Biol Sci. 2016;12(2):235–245. doi:10.7150/ijbs.1381426884720
   PubMed Web of Science ®Google Scholar
• HayashiD, ShiraiT, TerauchiR, et al. Pristimerin inhibits the proliferation of HT1080 fibrosarcoma cells by inducing apoptosis. Oncol Lett. 2020;19(4):2963–2970.32218852
   PubMed Web of Science ®Google Scholar
• ZhaoQ, LiuY, ZhongJ, et al. Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer in vitro and in vivo. Cell Death Discovery. 2019;5:125. doi:10.1038/s41420-019-0208-031396402
   PubMed Web of Science ®Google Scholar
• MatsuoK, GalsonDL, ZhaoC, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 2004;279(25):26475–26480. doi:10.1074/jbc.M31397320015073183
   PubMed Web of Science ®Google Scholar
• ParkYJ, YooSA, KimM, KimWU. The role of calcium-calcineurin-NFAT signaling pathway in health and autoimmune diseases. Front Immunol. 2020;11:195. doi:10.3389/fimmu.2020.0019532210952
   PubMed Web of Science ®Google Scholar